Irritable Bowel Syndrome

CHARLOTTE, N.C. — Treatment for irritable bowel syndrome with diarrhea should target bloating in addition to diarrhea and abdominal pain or discomfort, according to data presented at the ACG Annual Scientific Meeting.

CHARLOTTE, N.C. — Once daily plecanatide decreased symptom severity among patients with irritable bowel syndrome-constipation and severe abdominal pain and bloating, according to a poster presented at the ACG Annual Scientific Meeting.

An FDA advisory committee voted 9-4 in favor of the use of Xphozah as a monotherapy for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis.

Virtual integrated care platform, GI OnDemand, has partnered with Mindset Health, a hypnotherapy mobile app, just days after announcing its partnership with Trellus Health, an inflammatory bowel disease management solution.

Particulate matter and toxic release exposure correlated with a higher incidence of irritable bowel syndrome among a subset of California residents, according to data published in Clinical Gastroenterology and Hepatology.

Transcutaneous electrical acustimulation improved abdominal pain and constipation symptoms in patients with irritable bowel syndrome compared with a sham procedure, according to a study published in American Journal of Gastroenterology.

Ironwood Pharmaceuticals Inc. announced positive results from its phase 3 trial that evaluated Linzess for the treatment of pediatric patients with functional constipation, according to a company press release.

Although the FDA has granted tentative approval to Norwich Pharmaceuticals’ 200 mg generic rifaximin, Bausch Health asserted in a company statement that full approval will not be given until its own rifaximin patent expires in 2029.

Internet-delivered cognitive behavioral therapy may be a cost-effective solution to improve symptoms and quality of life in patients with irritable bowel syndrome, according to a systematic review in Journal of Medical Internet Research.

The AGA has issued clinical guidelines that outline a pharmacologic treatment plan for patients with irritable bowel syndrome and its subtypes, IBS-constipation and IBS-diarrhea, which were published in Gastroenterology.